scholarly journals Supplementation with Low Doses of a Cod Protein Hydrolysate on Glucose Regulation and Lipid Metabolism in Adults with Metabolic Syndrome: A Randomized, Double-Blind Study

Nutrients ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1991 ◽  
Author(s):  
Caroline Jensen ◽  
Hanna Fjeldheim Dale ◽  
Trygve Hausken ◽  
Jan Gunnar Hatlebakk ◽  
Ingeborg Brønstad ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Body Composition ◽  
Lipid Profile ◽  
Protein Hydrolysate ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Postprandial Glucose ◽  
Double Blind Study ◽  
Double Blind ◽  
Glucose Levels

The risk of cardiovascular diseases and type 2 diabetes mellitus are increased in subjects with metabolic syndrome (MetS), and hydrolyzed fish protein may have favorable effects on metabolic health. Here, we investigated the effect of 8 weeks supplementation with 4 g of cod protein hydrolysate (CPH) on glucose metabolism, lipid profile and body composition in individuals with MetS in a double-blind, randomized intervention study with a parallel-group design. Subjects received a daily supplement of CPH (n = 15) or placebo (n = 15). Primary outcomes were serum fasting and postprandial glucose levels. Secondary outcomes were fasting and postprandial insulin and glucagon-like peptide 1 (GLP-1), fasting lipid concentrations and body composition. No difference was observed between CPH and placebo for insulin, glucose or GLP-1 after 8 weeks intervention. Fasting triacylglycerol decreased in both the CPH group and placebo group, with no change between groups. Fasting total cholesterol and low-density lipoprotein cholesterol decreased significantly within both groups from baseline to study end, but no difference was observed between the two groups. In conclusion, supplementing with a low dose of CPH in subjects with MetS for 8 weeks had no effect on fasting or postprandial levels of insulin, glucose or GLP-1, lipid profile or body composition.

scholarly journals ASSOCIATION BETWEEN BLOOD LIPID PROFILE AND BLOOD GLUCOSE LEVELS IN MEN WITH CORONARY HEART DISEASE, METABOLIC SYNDROME, AND TYPE 2 DIABETES MELLITUS

2013 ◽  
Vol 12 (5) ◽  
pp. 29-33
Author(s):  
S. A. Matveeva
Keyword(s):  
Blood Glucose ◽  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Blood Lipid ◽  
Lipoprotein Cholesterol ◽  
Blood Lipid Profile ◽  
Glucose Levels ◽  
Blood Glucose Levels

Aim.To study the associations between blood lipid profile and blood glucose levels in men with coronary heart disease (CHD), stable effort angina (SEA), metabolic syndrome (MS), and Type 2 diabetes mellitus (DM-2).Material and methods.The study included 82 men (mean age 50,5±0,9 years) with CHD, Functional Class I–III SEA, MS, and DM-2. The following lipid profile parameters were assessed: total cholesterol (TCH), triglycerides (TG), low-density lipoprotein cholesterol (LDL–CH), very low-density lipoprotein cholesterol (VLDL–CH), high-density lipoprotein cholesterol (HDL–CH), atherogenic index (AI), and triglyceride index (TGI), together with fasting blood glucose.Results.There were positive (direct) associations between higher levels (>90th percentile) of lipid profile parameters (TCH, TG, LDL–CH, VLDL– CH, HDL–CH, AI, TGI) and blood glucose, as well as between lower levels (≤10th percentile) of lipid profile parameters (TCH, TG, LDL–CH, VLDL– CH, AI, TGI) and blood glucose. At the same time, there were negative (inverse) associations between lower lipid levels (≤10th percentile of TCH, TG, LDL–CH, VLDL–CH, HDL–CH, AI, TGI) and higher glucose levels (>90th percentile), as well as between higher lipid levels (>90th percentile of TCH, TG, LDL–CH, VLDL–CH, HDL–CH, AI, TGI) and lower glucose levels (≤10th percentile).Conclusion.Dyslipidemia and hyperglycemia demonstrate synergetic proatherogenic effects in patients with CHD, SEA, MS, and DM-2, as suggested by significant heterogeneous (direct and inverse) associations between lipid profile parameters and fasting blood glucose. The results obtained provide an opportunity for the assessment of risk levels, prognosis, and need for pharmacological prevention and treatment in patients with combined cardiovascular pathology. 

scholarly journals Daily Oral Administration of the Novel Androgen 11β-MNTDC Markedly Suppresses Serum Gonadotropins in Healthy Men

2020 ◽  
Vol 105 (3) ◽  
pp. e835-e847 ◽  
Author(s):  
Fiona Yuen ◽  
Arthi Thirumalai ◽  
Cindy Pham ◽  
Ronald S Swerdloff ◽  
Bradley D Anawalt ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Double Blind Study ◽  
Serious Adverse Events ◽  
Double Blind ◽  
Healthy Men ◽  
Drug Concentrations ◽  
Serum Gonadotropin

Abstract Background 11β-methyl-19-nortestosterone (11β-MNT) is a modified testosterone (T) with androgenic and progestational activity. A single oral dose of the prodrug, 11β-MNT dodecylcarbonate (11β-MNTDC), was well tolerated in healthy men. Methods We conducted a randomized, double-blind study at 2 academic medical centers. 42 healthy men (18–50 years) were randomized to receive oral placebo or 11β-MNTDC, 200 or 400 mg daily, for 28 consecutive days. Primary outcome (safety and tolerability) measures were assessed twice per week. Subjects underwent serial blood sampling over 24 hours on days 1 and 28 to assess secondary outcomes: pharmacokinetics (serum drug concentrations); pharmacodynamics of 11β-MNTDC (serum sex steroids and gonadotropins); and mood and sexual function (via validated questionnaires). Results There were no serious adverse events. No participants discontinued because of an adverse event or laboratory test abnormality. 11β-MNTDC resulted in a dose-related increase in serum 11β-MNTDC and 11β-MNT concentrations sustained over 24 hours. Administration of 11β-MNTDC resulted in a marked suppression of serum gonadotropins, T, calculated free T, estradiol, and SHBG over the treatment period (P < 0.01). Adverse effects that may be related to 11β-MNTDC included weight gain, acne, headaches, fatigue, and mild mood changes, with 5 men reporting decreased libido and 3 decreased erectile/ejaculatory function. Serum low-density lipoprotein cholesterol, weight (~2 kg), hematocrit, and hemoglobin increased and serum high-density lipoprotein cholesterol decreased in both 11β-MNTDC groups. Conclusion Daily oral 11β-MNTDC for 28 days in healthy men markedly suppressed serum gonadotropin and T concentrations without serious adverse effects. These results warrant further evaluation of 11β-MNTDC as a potential male oral contraceptive.

scholarly journals Body Composition, Lipid Profile, Adipokine Concentration, and Antioxidant Capacity Changes during Interventions to Treat Overweight with Exercise Programme and Whole-Body Cryostimulation

2015 ◽  
Vol 2015 ◽  
pp. 1-13 ◽  
Author(s):  
Anna Lubkowska ◽  
Wioleta Dudzińska ◽  
Iwona Bryczkowska ◽  
Barbara Dołęgowska
Keyword(s):  
Body Composition ◽  
Lipid Profile ◽  
Body Mass ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Exercise Programme ◽  
Whole Body ◽  
Antioxidant Enzyme Activities ◽  
Obese People ◽  
Sod Activity

The aim of this study was to determine the effect of six-month-long physical exercise programme with a two-time exposure to whole-body cryostimulation (WBC) in 20 sessions on antioxidant enzyme activities, lipid profile, and body composition changes in obese people (30 adult subjects; BMI = 30.39 ± 4.31 kg/m2). Blood samples were taken before the programme, one month following the exercise programme, before and after the first WBC treatment, six months following the exercise programme, after the second WBC treatment, and finally one month after the intervention. Six months of moderate aerobic activity combined with WBC did not change body mass or fat and lean body mass percentages, or circulating adiponectin, leptin, and resistin concentrations. In response to intervention a significant decrease in the level of low-density lipoprotein and triglycerides was observed, with a slight increase in high-density lipoprotein concentration. The nature of changes in the activity of respective antioxidant enzymes was not identical. After one month of increased physical activity, a significant decrease in superoxide dismutase, catalase, and glutathione reductase activities was observed (13%, 8%, and 70%, resp.). The SOD activity increased significantly after successive whole-body cryostimulation sessions. As regards catalase, a significant progressive decrease in its activity was observed.

Abstract 3733: Postprandial Free Fatty Acid Metabolism During Fenofibrate Treatment Predicts Postprandial Lipid And Lipoprotein Changes

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Robert S Rosenson
Keyword(s):  
Metabolic Syndrome ◽  
Test Meal ◽  
Low Density Lipoprotein ◽  
Area Under The Curve ◽  
Density Lipoprotein ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
The Metabolic Syndrome ◽  
Ldl Particles ◽  
Postprandial Triglycerides

Objective: To determine the effects of fenofibrate (160 mg/d) on fasting and postprandial non-esterified fatty acids (NEFA) and lipoproteins in subjects with hypertriglyceridemia and the metabolic syndrome. Methods: Fifty-nine subjects with fasting hypertriglyceridemia (≥1.7 mmol/L and <6.9 mmol/L) and two or more of the Adult Treatment Panel III criteria of the metabolic syndrome were randomized to fenofibrate (160 mg/d) or placebo in a double-blind controlled clinical trial. A standardized fat load (50 g/m 2 ) was given after a 12 h fast. Blood specimens were obtained at fasting and 3.5 h and 8 h after the test meal. Results: After the test meal, postprandial (area under the curve) NEFA increased (mean ± SEM) by 11.2 ± 5.1% in the placebo group; in contrast NEFA decreased by 18.6 ± 3.8% in the fenofibrate group ( P =0.0001). No differences in fasting NEFA were observed between groups ( P =0.16). Fenofibrate reduced postprandial triglycerides (−45.4%, P <0.0001) and significantly decreased postprandial large (−40.8%, P <0.0001) and medium (−49.5%, p<0.0001) very low-density lipoprotein (VLDL) particles, as well as small LDL (−40.3%, P <0.0001) and total LDL particles (−19.0%, P <0.005). Reduction in NEFA (AUC) correlated with reductions in postprandial triglycerides (r=0.73, P <0.0001), non-HDL-C (r=0.67, P <0.0001) and with increases in HDL-C (r=0.38, P <0.01). The reduction in NEFA was more strongly correlated with decreased large VLDL (r=0.72, P <0.0001) than medium VLDL (r=0.34, P <0.02) or small VLDL particles (r=0.22, P <0.13). Postprandial reductions in NEFA were also correlated with lowering of small LDL (r=0.53, P <0.0001) and total LDL particles (r=0.60, P <0.0001). Conclusions: Treatment with fenofibrate significantly decreases postprandial NEFA and the reductions in NEFA are highly correlated with reductions in triglycerides, non-HDL-C and an increase in HDL-C. Postprandial NEFA are an important predictor of postprandial lipoprotein changes in subjects with hypertriglyceridemia.

Investigation of ischemia modified albumin and coenzyme Q10 levels in obese children with metabolic syndrome

2016 ◽  
Vol 41 (6) ◽  
Author(s):  
Sabahattin Muhtaroğlu ◽  
Selda Özkan Koçak ◽  
İhsan Çetin ◽  
Didem Barlak Keti ◽  
Mustafa Kendirci
Keyword(s):  
Metabolic Syndrome ◽  
Lipid Profile ◽  
Low Density Lipoprotein ◽  
Colorimetric Method ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Healthy Children ◽  
Model Assessment ◽  
Obese Children ◽  
Ischemia Modified Albumin

AbstractIntroduction:The aim of this study was to analyze serum ischemia modified albumin (IMA) and plasma CoQ10 levels and to evaluate their correlation with insulin resistance (homeostatic model assessment, HOMA) and lipid profile in obese children with and without metabolic syndrome (MS).Methods:Thirty-one obese with MS, 30 obese without MS and 34 healthy children aged 6–18 years were included in the study. Serum IMA was measured by colorimetric method, plasma CoQ10 levels were measured by HPLC. Serum glucose, total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol and insulin were analyzed.Results:IMA levels were found to be significantly higher (p<0.001) while the CoQ10 levels were significantly lower (p<0.001) in obese children with and without MS compared to controls. IMA and CoQ10 significantly correlated with each other and metabolic parameters. Furthermore, IMA and CoQ10 levels did not significantly differ between obese children with and without MS, while glucose, insulin levels and HOMA were significantly higher (p<0.001) in obese children with MS than obese without MS and controls.Conclusions:Based on the high levels of IMA, low CoQ10 and association with HOMA and lipid profile; we suggest that obese children may have oxidative damage, lipid peroxidation and cardiometabolic risk.

scholarly journals A Review on the Protective Effects of Honey against Metabolic Syndrome

Nutrients ◽  
2018 ◽  
Vol 10 (8) ◽  
pp. 1009 ◽  
Author(s):  
Nur Ramli ◽  
Kok-Yong Chin ◽  
Khairul Zarkasi ◽  
Fairus Ahmad
Keyword(s):  
Metabolic Syndrome ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Therapeutic Agents ◽  
Protective Effects ◽  
Excessive Weight Gain ◽  
Glucose Levels ◽  
Blood Glucose Levels ◽  
Excessive Weight ◽  
Sugar Levels

Metabolic syndrome (MetS) is a cluster of diseases comprising of obesity, diabetes mellitus, dyslipidemia, and hypertension. There are numerous pre-clinical as well as human studies reporting the protective effects of honey against MetS. Honey is a nutritional food low in glycemic index. Honey intake reduces blood sugar levels and prevents excessive weight gain. It also improves lipid metabolism by reducing total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and increasing high-density lipoprotein (HDL), which leads to decreased risk of atherogenesis. In addition, honey enhances insulin sensitivity that further stabilizes blood glucose levels and protects the pancreas from overstimulation brought on by insulin resistance. Furthermore, antioxidative properties of honey help in reducing oxidative stress, which is one of the central mechanisms in MetS. Lastly, honey protects the vasculature from endothelial dysfunction and remodelling. Therefore, there is a strong potential for honey supplementation to be integrated into the management of MetS, both as preventive as well as adjunct therapeutic agents.

scholarly journals Investigation of the tolerability of oral stevioside in Brazilian hyperlipidemic patients

2006 ◽  
Vol 49 (4) ◽  
pp. 583-587 ◽  
Author(s):  
Gisleine Elisa Cavalcante da Silva ◽  
Abdol Hakin Assef ◽  
Claudio Cordeiro Albino ◽  
Letícia de Araujo Funari Ferri ◽  
Gilson Tasin ◽  
...  
Keyword(s):  
Laboratory Tests ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Stevia Rebaudiana ◽  
Severe Adverse Effect ◽  
Double Blind Study ◽  
Very Low Density Lipoprotein ◽  
Low Density ◽  
Double Blind ◽  
Selection Of

The tolerability of stevioside (2.75 mg/kg/day) obtained from leaves of Stevia rebaudiana (Bert) Bertoni (Compositae) was investigated in hyperlipidemic patients. For this purpose a placebo controlled double blind study was performed. The patients were randomized in two groups: the first group received capsules containing placebo and the second group received capsules containing stevioside (50 mg) during 90 days. All capsules were ingested twice daily, i.e., 2 capsules before lunch and 2 capsules before dinner. After the selection of the patients and each 30 days body mass index and laboratory tests (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase, total cholesterol, high density lipoprotein, low density lipoprotein, very low density lipoprotein, triglycerides and glucose) were performed. Stevioside did not show any clinical relevant modification in all parameters investigated. Moreover the patients did not report severe adverse effect. Thus, we can concluded that stevioside, at least in the doses employed in this study was safe.

scholarly journals Antibodies against phosphorylcholine in hospitalized versus non-hospitalized obese subjects

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Amra Jujić ◽  
J. Korduner ◽  
H. Holm ◽  
G. Engström ◽  
E. Bachus ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Smoking Status ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Glucose Levels ◽  
History Of ◽  
Obese Subjects ◽  
Anti Inflammatory

AbstractObesity associates with reduced life expectancy, type 2 diabetes, hypertension and cardiovascular disease, and is characterized by chronic inflammation. Phosphorylcholine (PC) is an epitope on oxidized low-density lipoprotein, dead cells and some microorganisms. Antibodies against PC (anti-PC) have anti-inflammatory properties. Here, we explored the role of anti-PC in hospitalized versus non-hospitalized obese. One-hundred-and-twenty-eight obese (BMI ≥ 30 kg/m2) individuals (59.8 (± 5.5) years, 53.9% women) from the Malmö Diet and Cancer Cardiovascular Cohort were examined and IgM, IgG1 and IgG2 anti-PC were analyzed by ELISA. Individuals with at least one recorded history of hospitalization prior to study baseline were considered hospitalized obese (HO). Associations between IgM, IgG1 and IgG2 anti-PC and HO (n = 32)/non-hospitalized obese (NHO) (n = 96), but also with metabolic syndrome and diabetes were analysed using logistic regressions. Both IgM and IgG1 anti-PC were inversely associated with HO, also after controlling for age and sex. When further adjusted for waist circumference, systolic blood pressure, glucose levels and smoking status, only IgG1 anti-PC remained significantly associated with HO. In multivariate models, each 1 standard deviation of increment in anti-PC IgG1 levels was inversely associated with prevalence of HO (odds ratio 0.57; CI 95% 0.33–0.98; p = 0.044). IgG2 anti-PC did not show any associations with HO. Low levels of IgM and IgG1 anti-PC are associated with higher risk of being a HO individual independent of sex and age, IgG1 anti-PC also independently of diabetes and metabolic syndrome. The anti-inflammatory properties of these antibodies may be related to inflammation in obesity and its complications.

Sign in / Sign up

Export Citation Format

Share Document